Stocks to Watch for September 15: HDFC Bank, BSE, IT Stocks, Coforge, Tata Chemicals and more

By Megha Rani  September 14, 2026, 11:05:00 AM IST (Published)

HDFC Bank | Sources tell CNBC-TV18 that the lender has short-listed two candidates as the next MD & CEO, including one internal and one external candidate. Kaizad M Bharucha, currently the Deputy Managing Director is among the two names short-listed, according to sources, while the external candidate is a top executive from a private bank. The HDFC Bank ADR was up 6.5% on Friday on Wall Street.

BSE, Angel One, Broking Stocks | As per the SEBI Consultation paper on CAS, suggestions on five topics have been shared, which include using blended Volume Weighted Average Price for 30 minutes of normal cash trading and 10 minutes of CAS, going back to the old VWAP system for now, normal cash trading for CAS stocks till 3:30, no live indicative index values during CAS, a clamp down on spoofing and bringing iceberg orders into CAS. Jefferies says these proposals remove uncertainty and is positive for brokers and exchanges.

IT Stocks | India's IT companies will be in focus on Tuesday after chiefs of OpenAI, Anthropic and China's Security chief have all called for a slowdown in the development of AI. Most of the AI-linked stocks in the global markets have reacted negatively to this development.

Tata Chemicals, Other Tata Group Stocks | Sources tell CNBC-TV18 that the Reserve Bank of India has rejected Tata Sons' application, meaning Tata Sons will have to list in accordance with the RBI guidelines. Tata Sons' application for voluntary surrender of the certificate of registration has been rejected.

Coforge | The firm said DK Singh has resigned as an independent director and chairperson of its Nomination and Remuneration Committee (NRC) with immediate effect. Beth Boucher has been appointed as the new NRC chairperson. Singh cited tensions between executive and independent directors, while Board Chair OP Bhatt had resigned on September 8 after Advent voted against his reappointment.

Sun Pharma | The pharma major said its subsidiaries have reached a settlement with a plaintiff in the US generic drug pricing antitrust litigation for a confidential amount. The settlement involves Sun Pharmaceutical Industries Inc., Taro Pharmaceutical Industries and Taro Pharmaceuticals USA Inc in the case pending before the Eastern District of Pennsylvania.

Granules India | Drug manufacturer said promoter Dr Krishna Prasad Chigurupati sold 1.72 crore shares on September 11 through block and open-market transactions. The sale included participation from institutional investors and was undertaken to fund the second tranche of the company’s preferential issue and support its growth plans.

Jubilant Pharmova | The pharma company said the US FDA has classified its CMO facility in Spokane, Washington, as “Voluntary Action Indicated” (VAI) following an inspection conducted from June 8-17, 2026.

HDFC Life Insurance | The insurer said the Commissioner (Appeals-III), CGST & Central Excise, Mumbai, has confirmed the GST demand, interest and penalty for the period July 2017 to March 2022. The case involves a tax demand of ₹942.18 crore and a penalty of ₹2,422.97 crore, plus applicable interest.

Raymond | The firm said its aerospace subsidiary has secured new business from a leading Indian aerospace and defence major, with annual potential of around ₹33 crore. The orders cover over 300 part numbers and more than 37,000 components annually, with production set to begin progressively in 2026 and 2027.

Aurobindo Pharma | The drugmaker said the US FDA has concluded an inspection at its API manufacturing unit in Andhra Pradesh with zero observations. The inspection was conducted from September 7 to 11, 2026.